Syntermed licenses imaging technology from Emory for heart failure evaluation
New imaging software, which uses multiharmonic phase analysis to allow physicians to more accurately diagnose and treat patients with heart failure, has been licensed by Emory University to Syntermed, an Atlanta-based nuclear medicine imaging and informatics software company.
The MHPA, developed by Emory medical scientists Ernest Garcia, PhD, and Ji Chen, PhD, in Atlanta, is designed to quickly determine which heart failure patients will benefit from cardiac resynchronization therapy (CRT). CRT is used to improve heart function by restoring the correct mechanical sequence of heart contractions in patients with an irregular heartbeat, called left ventricular dyssynchrony.
Syntermed will market the MHPA-based software as SyncTool, designed to provide improvements over TDI echo technology. Advances include additional image clarity, 3D perfusion images, an automated process that eliminates variations in interpretation, and rapid and objective physician assessment of dyssynchrony in heart failure patients, the company said.
SyncTool will be added as a new tool to the Emory Cardiac Toolbox.
The MHPA, developed by Emory medical scientists Ernest Garcia, PhD, and Ji Chen, PhD, in Atlanta, is designed to quickly determine which heart failure patients will benefit from cardiac resynchronization therapy (CRT). CRT is used to improve heart function by restoring the correct mechanical sequence of heart contractions in patients with an irregular heartbeat, called left ventricular dyssynchrony.
Syntermed will market the MHPA-based software as SyncTool, designed to provide improvements over TDI echo technology. Advances include additional image clarity, 3D perfusion images, an automated process that eliminates variations in interpretation, and rapid and objective physician assessment of dyssynchrony in heart failure patients, the company said.
SyncTool will be added as a new tool to the Emory Cardiac Toolbox.